The Real Cost of Compounded Semaglutide in 2026: What You'll Pay

Last Updated: January 2026

Compounded semaglutide now costs between $99 and $549 per month depending on provider and dose tier, according to a January 2026 analysis of 14 major telehealth platforms—a price point roughly 75% below Wegovy's $1,349 list price. The FDA removed semaglutide from its drug shortage list in October 2024, but compound pharmacies continue operating under enforcement discretion that may tighten within the next 18 months. The gap between what patients pay and what they're actually getting has never been wider.

The compounded GLP-1 market has fractured into three distinct pricing tiers. Budget operators like Strut and Eden charge $99 to $199 per month for starting doses, mid-tier providers including BreezeMeds and Hims cluster around $249 to $299, and premium platforms like Mochi Health push into the $400 to $549 range. These numbers reflect out-of-pocket costs with provider consultation included, but the composition of what you receive at each price point varies dramatically.

What the Price Actually Includes

Most providers bundle four components into their monthly fee: the compounded semaglutide itself, prescriber consultation, pharmacy dispensing, and shipping. The clinical oversight piece is where cost structures diverge. A 2024 study published in the Journal of Medical Internet Research found that 68% of direct-to-consumer telehealth GLP-1 programs required less than 10 minutes of actual physician contact for initial prescriptions. The $99 programs typically offer asynchronous messaging with nurse practitioners. The $500 programs advertise continuous glucose monitoring, dietitian access, and monthly video check-ins.

What's conspicuously absent from most pricing: standardized potency testing. Compounded drugs aren't subject to FDA bioequivalence requirements. A September 2025 investigation by the Alliance for Pharmacy Compounding tested 11 semaglutide samples from 503A pharmacies and found potency ranging from 87.3% to 112.6% of stated dose. Two samples contained bacterial endotoxin levels above USP standards. None of this information appears on provider websites.

503A vs 503B: The Pharmacy Distinction That Changes Everything

The compounding pharmacy type matters more than the telehealth brand name on your browser tab. Section 503A facilities compound patient-specific prescriptions and operate under state pharmacy boards. Section 503B outsourcing facilities follow current Good Manufacturing Practices and register with the FDA. The distinction shows up in testing protocols, sterility assurance, and traceability.

503B pharmacies conduct sterility testing on every batch, maintain cleanroom standards comparable to pharmaceutical manufacturers, and submit to FDA inspection. 503A pharmacies test based on state requirements—which in 31 states means no mandatory sterility testing for injectable compounded drugs. A 2024 CDC report documented 47 adverse events linked to compounded weight loss injections, with 83% traced to 503A facilities.

Most budget providers source from 503A pharmacies. Platforms charging above $350 per month tend to use 503B facilities, though they rarely volunteer this information upfront. You have to read supplier disclosures in account settings or email customer service directly. When I contacted 14 platforms in December 2025 asking about their pharmacy partners, eight responded within 48 hours, three gave vague answers about "licensed US pharmacies," and three never replied.

Provider	Monthly Cost (Starting Dose)	Pharmacy Type	Potency Testing	Prescriber Credential
Strut	$99	503A	Not disclosed	NP/PA
Eden	$199	503A	Certificate of Analysis available	MD/NP
BreezeMeds	$249	503A	Not disclosed	NP
Hims	$299	503A	Third-party tested (per website)	MD/NP
Mochi Health	$549	503B	Batch-level sterility and potency	MD

Dose Escalation Changes the Math

Advertised starting prices reflect 0.25 mg weekly dosing—the first month of a standard escalation protocol. Therapeutic doses for weight loss typically land between 1.7 mg and 2.4 mg weekly. At those levels, monthly costs jump considerably. A provider charging $199 for starting dose often charges $349 to $399 for maintenance dosing. This isn't price gouging—higher doses require more API and larger vial configurations.

The clinical question is whether you'll need those higher doses. Retrospective data from the STEP trials showed 36.8% of participants achieved clinically significant weight loss (≥5% body weight) on 1.0 mg weekly semaglutide versus 69.1% on 2.4 mg. The FDA-approved Wegovy protocol escalates to 2.4 mg over 16 weeks. Most compounding providers use faster escalation schedules—reaching 2.4 mg in 8 to 12 weeks—which means you hit the higher price tier sooner.

The Salt Form Variables

Compounding pharmacies use semaglutide base, semaglutide sodium, or semaglutide acetate. Novo Nordisk's branded products use semaglutide base. The different salt forms have slightly different molecular weights, which means dose conversions aren't exactly 1:1. A 2025 pharmacokinetic analysis in Clinical Pharmacology & Therapeutics found semaglutide sodium required roughly 6% higher mass to achieve equivalent plasma concentrations compared to semaglutide base.

Most compounding pharmacies don't disclose which salt form they're using. Of the 14 platforms I surveyed, only two specified the salt form on their FAQ pages. The rest required direct inquiry. This matters because a pharmacy using semaglutide sodium but labeling vials simply as "semaglutide 2.4 mg" may be delivering subtherapeutic dosing. The price looks identical, but the pharmacology isn't.

Quality Indicators You Can Actually Check

Before transferring payment information, verify these four elements. First, confirm the prescribing clinician is licensed in your state. Telehealth prescribing follows state medical boards, not federal rules. Second, ask explicitly whether the pharmacy is 503A or 503B and request the facility name. Cross-reference it against FDA warning letters—the agency publishes enforcement actions publicly. Third, request a Certificate of Analysis for potency and sterility. Legitimate pharmacies provide this for each batch. Fourth, check whether the platform requires lab work before prescribing.

Providers that skip baseline metabolic panels and lipase testing are cutting corners that show up in adverse event rates. A 2024 analysis published in Obesity found that patients who received laboratory screening before GLP-1 initiation had a 43% lower rate of treatment discontinuation due to side effects compared to those prescribed after questionnaire-only evaluation. The $99 providers rarely require labs. The $400-plus providers usually do.

The Regulatory Overhang

Current pricing exists in a temporary regulatory window that's visibly closing. The FDA stated in their October 2024 shortage resolution announcement that compounding of semaglutide may continue during a "transition period" but did not specify an end date. Novo Nordisk has petitioned the FDA to use its enforcement discretion authority to stop compounding of semaglutide products, arguing that the complexity of the drug and delivery device makes it inappropriate for compounding.

If the FDA moves to restrict compounding, the budget tier disappears overnight. Patients currently paying $199 per month would face a choice between discontinuing treatment or switching to branded products at seven times the cost. The mid-tier and premium providers have more regulatory cushion—some are already transitioning to branded semaglutide distribution agreements—but the $99 to $199 price point depends entirely on continued enforcement discretion.

The economic reality is that compounded semaglutide prices reflect the FDA looking the other way, not sustainable market equilibrium. As the New England Journal of Medicine noted in a November 2024 editorial: "The compounded GLP-1 market exists in the space between shortage necessity and regulatory tolerance—a space that historically collapses once the precipitating shortage resolves."

Insurance and FSA Eligibility

Compounded medications are almost never covered by insurance. The few exceptions involve patients with documented adverse reactions to branded formulations who obtain prior authorization for compounded alternatives. Flexible Spending Accounts and Health Savings Accounts generally reimburse compounded GLP-1s if prescribed for diabetes (ICD-10 code E11) but not for obesity (E66). This creates predictable documentation games where providers emphasize prediabetes and insulin resistance to improve reimbursement odds.

The practical effect: the sticker price is your actual price. Unlike branded Wegovy, where list price and net price diverge wildly due to rebates and copay assistance, compounded semaglutide costs exactly what the checkout page says. For patients with BMI above 30 and household income below $75,000, this makes compounding financially superior despite quality uncertainty. For patients with comprehensive insurance and BMI above 27 with comorbidities, branded products often cost less after copay assistance.

Storage and Wastage Costs

Compounded semaglutide arrives in multi-dose vials requiring refrigeration and sterile handling. Patients self-inject using insulin syringes, which aren't included in most program pricing. A box of 100 insulin syringes costs $15 to $25. Alcohol prep pads add another $8 per month. Sharps disposal containers run $12 to $20 depending on size. These ancillary costs add $30 to $45 monthly—a 15% to 45% surcharge on budget-tier programs that rarely appears in advertised pricing.

Vial wastage creates hidden costs too. Most compounding pharmacies dispense 2 mL or 5 mL vials. If your dose doesn't divide evenly into the vial volume, you'll discard active medication. A 5 mL vial containing 10 mg semaglutide (2 mg/mL concentration) provides four 1.0 mg doses with 6 mg wasted or four 2.4 mg doses with 0.4 mg remaining. Pharmacies could optimize vial concentrations to minimize waste, but most use standardized formulations across dose tiers.

What Actually Drives Price Differences

The cost to compound a single semaglutide vial—including API, pharmacy labor, sterility testing, and shipping—runs between $40 and $120 depending on 503A versus 503B standards. The remaining $100 to $400 of monthly program fees covers prescriber time, telehealth platform maintenance, customer service, and profit margin. The budget providers minimize prescriber involvement, automate refills, and operate on volume. The premium providers employ physicians instead of nurse practitioners, conduct video consultations, and offer comprehensive metabolic monitoring.

Neither model is inherently superior for all patients. A healthy 42-year-old with BMI 32, normal labs, and no medications might do fine with a $199 program and asynchronous messaging